Study Summary
This trial will investigate whether the use of stereotactic ablative radiosurgery (SABR) is a non-invasive, effective alternative treatment for renal tumors in patients who are not suitable candidates for surgery.
- Kidney Tumors
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: 2 years
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Stereotactic Ablative Radiotherapy
1 of 1
Experimental Treatment
30 Total Participants · 1 Treatment Group
Primary Treatment: Stereotactic Ablative Radiotherapy · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What is the scope of patients receiving treatment as part of this experiment?
"Affirmative. Clinicaltrials.gov confirms that this clinical trial, which was first made public on the 1st of November 2018, is still searching for participants. There are 30 spots available to be filled at two different sites." - Anonymous Online Contributor
Has enrollment opened for this experiment yet?
"The clinical trial, which was initially launched on November 1st 2018, is still recruiting patients according to the information found on clinicaltrials.gov. The last update occurred October 17th 2022." - Anonymous Online Contributor